It looks like generic drugs are getting a reprieve from tariffs. Pharma shares climbed up to 4% on Oct. 9 after a report said President Donald Trump isn’t planning to impose tariffs on generic drugs from foreign countries.
A Wall Street Journal (WSJ) report said that the move to exclude generic medicines from tariffs is not yet final but is being considered seriously. It also added that the decision could change in the coming weeks depending on ongoing internal discussions within the administration.
READ: NBFCs diversify as US, Canada student loan disbursements take a hit (
WSJ also reported Wednesday that President Trump’s administration was exploring other alternative measures such as federal grants or loans to encourage domestic production of critical generic drugs, aiming to reduce reliance on foreign suppliers, including India.
“The administration is not actively discussing imposing Section 232 tariffs against generic pharmaceuticals,” said Kush Desai, deputy press secretary of the White House, according to The Wall Street Journal. Desai said the administration was pursuing “a nuanced and multi-faceted approach to onshore manufacturing of generic pharmaceuticals” to avoid future dependence like that seen during the Covid era, according to the report.
Generic medications make up about 90% of all prescriptions in the U.S., providing affordable treatment options for millions of patients. Many of these drugs are imported, especially from India, which is a global leader in producing cost-effective generics. Tariffs on these drugs risked increasing prices for patients, straining healthcare providers, insurers, and government programs like Medicare and Medicaid.
The decision to exclude generics was announced to prevent disruptions in the medicine supply chain and protect vulnerable populations relying on affordable medications.
This move also helped maintain positive trade relations with India, a crucial pharmaceutical supplier to the U.S.
While there is a clear desire to encourage domestic manufacturing and reduce dependency on foreign sources—especially highlighted by shortages experienced during the COVID-19 pandemic—immediate measures like tariffs can have unintended consequences. By avoiding tariffs on generics, the administration is signaling its awareness that abrupt disruptions in critical supply lines can harm vulnerable populations and healthcare systems.
Moving forward, the focus may shift toward more strategic, long-term investments and partnerships that strengthen domestic capabilities without compromising access or affordability. This approach reflects a growing understanding that resilience in essential industries like pharmaceuticals requires cooperation, innovation, and balanced policy-making rather than protectionism alone.